Long term follow-up of refractory/relapsed hairy cell leukaemia patients treated with low-dose vemurafenib between 2013 and 2022 at the Department of Internal Medicine and Oncology, Semmelweis University

Long term follow-up of refractory/relapsed hairy cell leukaemia patients treated with low-dose vemurafenib between 2013 and 2022 at the Department of Internal Medicine and Oncology, Semmelweis University

Introduction: Hairy cell leukemia (HCL) is an indolent B-cell lymphoproliferative disease. BRAF V600E mutation is detected in nearly all classical HCL cases which offers the possibility of targeted therapy.Objective: The aim of our study was to assess the efficacy of low-dose vemurafenib as well as...

Full description

Bibliographic Details
Main Authors: Kata Ferenczi, Zsófia Flóra Nagy, Ildikó Istenes, Hanna Eid, Csaba Bödör, Botond Timár, Judit Demeter
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Pathology and Oncology Research
Subjects:
relapsed/refractory
infection
hairy cell leukemia
BRAF inhibitors
vemurafenib
Online Access:https://www.por-journal.com/articles/10.3389/pore.2023.1611378/full

Internet

https://www.por-journal.com/articles/10.3389/pore.2023.1611378/full

Similar Items